Trial Profile

Hepatocyte Growth Factor to Improve Functioning in Peripheral Artery Disease: The HI-PAD Study

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Donaperminogene seltoplasmid (Primary)
Indications Peripheral arterial disorders
Focus Therapeutic Use
Acronyms HI-PAD

Most Recent Events

01 Jun 2025 Primary endpoint has not been met. (Six-minute walk distance)
01 Jun 2025 Results assessing VM202 to improve walking performance in people with mild to moderate and symptomatic lower extremity peripheral artery diseasepublished in the Journal of Vascular Surgery
01 Nov 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com